Terumo has received the actual device for evaluation; therefore, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and more information becomes available.For this reason, terumo referenced evaluation (b)(4).(b)(4).
|
This follow-up report is submitted to the fda in accord with applicable regulations - and as indicated by terumo cardiovascular system in the initial report submitted to the fda on february 1, 2017.Method: actual device evaluated; visual inspection; storage and shipment review.Results: shipping problem.Conclusions: human factors issue.The returned sample was visually inspected, during which it was found that a sterilization tag was still present on the outer carton.The shipment of this product was traced and it was determined that the carton was sent to sterilization from (b)(4) after manufacturing, with the sterilization tag present.After sterilization, the product was sent directly to the distribution center in tennessee, where the tag was not removed.The product was then delivered to the customer with the tag still remaining on the carton.When the product was shipped from sterilization to the distribution center directly, the awaiting sterilization tag should have been removed by an associate prior to shipping to the customer.All available information has been placed on file in quality management for appropriate tracking, trending and follow up.
|